Skip to content
Clinical Trials – home

Centre Hospitalier Universitaire De Nice

Verified siteinfo

France 30 Voie Romaine, 06000 Nice, France

  • 12 trials recruiting
  • Acute myeloid leukaemia · Cerebrovascular accident prophylaxis · Idiopathic pulmonary fibrosis
  • Adults and children

About Specializations

Centre Hospitalier Universitaire De Nice in Nice, France specialises in clinical trials of conditions such as Acute myeloid leukaemia, Cerebrovascular accident prophylaxis, Idiopathic pulmonary fibrosis, Ischaemic stroke, and other specialisations. This site conducts important research.

Main research areas of the site

Nervous System Diseases

At Centre Hospitalier Universitaire De Nice, the Neurology department is involved in research on Nervous System Diseases, with a strong focus on conditions such as multiple sclerosis, Parkinson’s disease, generalized myasthenia gravis, and facioscapulohumeral muscular dystrophy. These studies are designed to assess new treatment options, compare established therapies, and better understand how to slow disease progression and improve daily function.

  • Testing therapies for multiple sclerosis to reduce disease activity and support long-term control
  • Evaluating treatment approaches for Parkinson’s disease to delay motor decline
  • Studying new options for myasthenia gravis and other neuromuscular disorders

This area reflects a broad effort to improve both symptom management and long-term outcomes for people living with complex neurological conditions.

Cardiovascular and Stroke Research

The site is also active in Cardiovascular Diseases, including studies in acute coronary syndrome, atherosclerotic cardiovascular disease, atrial fibrillation, and stroke prevention. Research here aims to test whether new treatments can lower the risk of heart attack, stroke, and other major cardiovascular events while balancing safety concerns such as bleeding risk.

  • Assessing therapies to reduce recurrent events after acute coronary syndrome
  • Improving prevention of ischemic stroke in high-risk patients
  • Comparing treatment strategies for atrial fibrillation to prevent stroke or systemic embolism

These studies support better prevention and long-term management of serious vascular disease in patients at elevated risk.

Respiratory and Interstitial Lung Disease

Clinical trials at this hospital in Nice include important work in Respiratory Tract Diseases, especially idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, interstitial lung disease, bronchiectasis, and asthma. The main goal is to evaluate therapies that may improve lung function, reduce flare-ups, and slow worsening of chronic lung disorders.

  • Testing treatments for pulmonary fibrosis and related scarring conditions
  • Studying care options for bronchiectasis and early airway infections
  • Evaluating new approaches for severe asthma in children and adolescents

This research area is centered on finding better ways to preserve breathing capacity and quality of life in patients with chronic respiratory disease.

Rheumatology and Immune-Mediated Disease

The research portfolio also covers Immune System Diseases and Musculoskeletal Diseases, with studies in rheumatoid arthritis, dermatomyositis, and systemic sclerosis-associated interstitial lung disease. These trials are focused on comparing treatment strategies, reducing inflammation, and improving symptoms and physical function in autoimmune conditions.

  • Comparing therapies for rheumatoid arthritis to improve remission rates
  • Exploring new treatments for dermatomyositis and related muscle inflammation
  • Assessing immune-targeted approaches in systemic sclerosis-related lung involvement

This work highlights the site’s role in advancing care for chronic inflammatory diseases that can affect both joints and internal organs.

Other Specialized Clinical Research

Beyond the major disease groups, Centre Hospitalier Universitaire De Nice contributes to studies in Analytical, Diagnostic and Therapeutic Techniques and Equipment, including research aimed at improving procedures and treatment support. One example is work on kidney stone management, where trials assess whether new supportive strategies can improve stone clearance and recovery after treatment.

  • Improving outcomes in kidney stone treatment
  • Supporting better procedural results in urological care
  • Evaluating practical ways to enhance treatment effectiveness across specialized care settings

This mixed research activity shows a broad commitment to refining patient care across several clinical fields, not only disease treatment but also the tools and approaches used to deliver it.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
30 Voie Romaine06000 NiceFrance
Recruiting now
12 trials
Conditions studied
37
Partner status
Verified site

More sites in NiceFrance

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

34 clinical trials

Countries:FranceFrance
  • Participants:18–64 years
  • Sponsor:Zenas Biopharma (USA) LLC

A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study Evaluating Direct Oral Anticoagulants for Prevention of Blood Clots in Patients with Hypertrophic Cardiomyopathy and Abnormal Left Atrial Function

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rivaroxaban
  • Sponsor:Centre Hospitalier Universitaire De Rennes

Bronchiectasis

Recruiting

Study Comparing Ciprofloxacin, Colistimethate Sodium, and Ceftazidime for Treating Early Airway Infection in Adults with Bronchiectasis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ciprofloxacin
  • Sponsor:Centre Hospitalier Intercommunal Creteil

Study on Long-Term Safety of Tolebrutinib and Teriflunomide for Patients with Multiple Sclerosis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Teriflunomide
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on Nipocalimab for Adults with Generalized Myasthenia Gravis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Nephrolithiasis

Recruiting

Study on the Effect of Furosemide and Amiloride Hydrochloride on Kidney Stone Fragments After Laser Treatment in Patients Undergoing Flexible Ureteroscopy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Furosemide
  • Sponsor:Centre Hospitalier Regional Universitaire De Tours

Study on Abatacept for Rheumatoid Arthritis in Patients Responding to Initial TNF Inhibitor Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abatacept
  • Sponsor:Centre Hospitalier Universitaire De Montpellier

Study Comparing CPX-351 and Chemotherapy for Patients with New Intermediate or High-Risk Acute Myeloid Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Centre Hospitalier Universitaire De Nice

Study on the Effects and Safety of Alpelisib for Children and Adults with Megalencephaly-Capillary Malformation Polymicrogyria Syndrome

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Alpelisib
  • Sponsor:Centre Hospitalier Universitaire De Dijon

Study on the Effectiveness and Safety of Rituximab for Patients with Progressive Interstitial Lung Disease with Inflammation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Centre Hospitalier Regional Universitaire De Tours

Study on the Effects of Annual vs. Semi-Annual Ocrelizumab Infusions in Patients with Active Multiple Sclerosis After 2 Years of Initial Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ocrelizumab
  • Sponsor:Fondation A De Rothschild
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.